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Speech treatment for people with hereditary ataxia – a feasibility study
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Patient Perceptions* No. of 
reports/19
Louder speech 14
Clearer speech 13
Longer phrases/speaking time 13
Better pacing / breath management 4
Better pitch/loudness control 2
Corroboration by others 7
Increased confidence / reduced anxiety 10
Background
• Communication impairment affects quality of life
• Little information available on how best to manage speech impairment in 
progressive ataxia
• At the start of our trial, no SLT studies published on this patient group, since 
then, 1 pilot study report on 7 patients with ARSACS1
• Lee Silverman Voice Treatment (LSVT)2: originally designed for Parkinson’s 
Disease, also shown benefits for other disorders (stroke, TBI, MS, CP)
appropriate for speakers with ataxia?
Aim & Objectives:
Perform a feasibility study into the effectiveness and acceptability of LSVT to 
improve communication in people with dysarthria due to hereditary ataxia.
1. Does LSVT result in positive changes to communication immediately following 
and 2 months post-treatment in speakers with hereditary ataxia and 
dysarthria?
2. Does LSVT lead to any undesirable outcomes in this population, such as 
increased fatigue level, or impact on voice quality?
3. What is the patient’s experience of LSVT delivered by Skype as a treatment 
regime?
Methods
Participants
• 21 patients recruited, 20 started and 19 completed treatment
• 18 FA, 1 SCA6, 1 SPG7, 1 unspecified CA
• Age range 19 – 75 years, 10 male, 10 female
• Speech severity level: mild – severe
Assessment:
• 2 baseline assessments
• 2 post-treatment assessment (immediate and @ 8 weeks)
• Administered via Skype
Assessment tasks:
• Prolonged /a/, Reading passage, Monologue, Impact/fatigue questionnaires, 
Participant interview
Outcome measures:
• Loudness, Voice quality, Prolonged vowel length, Phrase length, Intelligibility, 
Naturalness, Psychosocial impact, Fatigue
Treatment:
• LSVT-X – 16 sessions @ 2 sessions a week over 8 weeks, administered via Skype
Results
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Reading Data
Intelligibility Naturalness
p=.813
p=.989
I’m not worried that 
people will ask me to 
repeat anymore
I used to avoid 
phone 
conversations but 
I’m fairly confident 
now
Because of the changes in 
my voice I used to sound 
anxious in meetings, but 
now that I have the 
strategies my presentation 
went really well
I find it easier to 
complete all the 
syllables now
It’s helped me to 
control my voice
Before it took a lot 
more effort to 
pronounce words
Before, I’d say “I can’t be 
bothered”, but now I’ve 
been able to be more 
involved in conversationI recently met with some 
college friends who I’d 
not seen for 2 years and 
they thought I sounded 
better than last timeDiscussion
Treatment outcomes:
LSVT-X was beneficial for patients, cf 3
• Improved voice quality
• Improved breath support
• Patient perceived benefits for communication 
and confidence
• BUT – no listener perceived changes to 
intelligibility and naturalness – different to 1, 3
Treatment delivery:
• No negative impact on fatigue levels or voice
• 18/19 participants preferred Skype delivery to 
face to face
• Some issues with adherence due to prolonged 
treatment schedule – 4 weeks intensive 
delivery might be preferable
Special thanks to 
all our participants 
and
our funders
Conclusion
Speech therapy can be beneficial 
for people with ataxia’s 
communication and psychosocial 
wellbeing
* 15/19: considerable benefit; 2/19: a little benefit, 2/19: no benefit
length in sec, jitter & 
shimmer in %
p=.002
p =.014
p =.008
p <.000
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